Pier Capital LLC Makes New $3.26 Million Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Pier Capital LLC purchased a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 469,547 shares of the company's stock, valued at approximately $3,259,000. Pier Capital LLC owned about 0.12% of GoodRx at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of GDRX. Liontrust Investment Partners LLP purchased a new stake in shares of GoodRx during the second quarter worth about $520,000. Raymond James & Associates raised its position in GoodRx by 212.6% during the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company's stock valued at $2,734,000 after purchasing an additional 267,951 shares during the last quarter. Legato Capital Management LLC purchased a new stake in GoodRx in the 2nd quarter worth approximately $805,000. Dynamic Technology Lab Private Ltd grew its position in shares of GoodRx by 260.7% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company's stock worth $308,000 after buying an additional 32,104 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of GoodRx during the second quarter valued at approximately $843,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Stock Up 0.2 %

Shares of NASDAQ:GDRX traded up $0.01 on Friday, hitting $4.91. 922,616 shares of the company traded hands, compared to its average volume of 2,164,503. GoodRx Holdings, Inc. has a 52 week low of $4.09 and a 52 week high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a 50 day simple moving average of $5.80 and a 200-day simple moving average of $7.16. The company has a market cap of $1.87 billion, a PE ratio of -163.67, a PEG ratio of 3.69 and a beta of 1.29.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GDRX. Mizuho assumed coverage on GoodRx in a research note on Wednesday. They issued a "neutral" rating and a $5.00 price target for the company. Citigroup dropped their target price on shares of GoodRx from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. Finally, Barclays lowered their price objective on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $8.60.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.